← All trials
NCT07185997
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2025
- Primary completion
- Feb 28, 2029
- Completion date
- Dec 31, 2030
- First posted
- Sep 22, 2025
- Last posted
- Nov 19, 2025
- Enrollment
- 480
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ArriVent BioPharmaLead sponsor
- ArriVent BioPharmaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.